Form 8-K - Current report:
SEC Accession No. 0001731122-22-000164
Filing Date
2022-02-04
Accepted
2022-02-04 07:38:42
Documents
13
Period of Report
2022-02-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e3471_8-k.htm   iXBRL 8-K 27660
2 EXHIBIT 99.1 e3471_ex99-1.htm EX-99.1 9163
  Complete submission text file 0001731122-22-000164.txt   212685

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE avxl-20220204.xsd EX-101.SCH 3027
4 XBRL LABEL FILE avxl-20220204_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE avxl-20220204_pre.xml EX-101.PRE 22591
7 EXTRACTED XBRL INSTANCE DOCUMENT e3471_8-k_htm.xml XML 3609
Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37606 | Film No.: 22590987
SIC: 2836 Biological Products, (No Diagnostic Substances)